Select a search constraint:

ARROW® ErgoPack™

Infection control and protection

Risks associated with central line–associated bloodstream infections (CLABSIs)

Each year, more than 248,000 patients develop a CLABSI, resulting in more than 30,000 annual deaths. A single CLABSI can lead to more than $36,000 of expenses for your institution.1 Combine those statistics with the facts that mandatory public reporting of CLABSIs is looming and that consistently following maximal barrier precautions reduces the incidence of CLABSIs,2-4 and it is clear that you need a complete vascular access system designed to help protect against infections and their associated expenses.

The Arrow ErgoPack System provides defense against infection

To help reduce CLABSI-associated expenses, the Arrow ErgoPack System, when combined with the ARROWg+ard Blue PLUS® or Chlorag+ard® antimicrobial catheter technology, provides defense against all 5 sources of bloodstream infection, including:

  • Environmental contamination3,4
  • Skin organisms5
  • Post-placement subcutaneous tract infection6
  • Intraluminal contamination7
  • Hematogenous seeding8,9

The Arrow ErgoPack System features ARROWg+ard® antimicrobial technology

ARROWg+ard, a chlorhexidine silver sulfadiazine technology impregnated into the catheter surface, is a CDC1A recommendation for the prevention of catheter-related infection.5

ARROWg+ard reduces catheter-related bacteremia by 79%8 and is effective against a wide array of gram-positive bacteria, including Staphylococcus epidermidis,
methicillin-resistant Staphylococcus aureus (MRSA) and S. aureus; gram-negative bacteria, including Enterococci and Pseudomonas species; and fungi, including Candida albicans.10

ArrowEVOLUTION with Chlorag+ard® technology

ArrowEVOLUTION with Chlorag+ard® technology is the first chlorhexidine-treated peripherally inserted central catheter (PICC) with both intraluminal and extraluminal protection10 to offer:

  • Broad-spectrum activity against gram-positive, gram-negative and fungal pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), S. epidermidis, C. albicans and Acinetobacter baumannii10
  • Proven reduction of 99.99% of bacterial and fungal colonization (based on in vitro data)10

Sharps safety with the ARROW ErgoPack System

According to the National Institute for Occupational Safety and Health, 385,000 healthcare workers are injured by sharps every year, putting them at risk of exposure to bloodborne pathogens such as hepatitis B, hepatitis C and HIV.11 Also, there are numerous risks and complications associated with catheter insertion, including hematoma, pneumothorax, thrombosis and stenosis. A variety of factors can cause these complications, including multiple attempts to achieve successful cannulation and weak or compromised vasculature.

The upgraded sharps safety devices in the Arrow ErgoPack System protect your staff and enable your institution to classify its central venous catheter insertion kits as “evaluated” and “implemented,” as directed under the Needlestick Safety and Prevention Act and enforced by the Occupational Safety and Health Administration (OSHA).

ARROW, ArrowEVOLUTION, ARROWg+ard, ARROWg+ard Blue PLUS, Chlorag+ard and ErgoPack are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

References: 1. HHS action plan to prevent healthcare-associated infections: introduction. US Department of Health and Human Services Web site. Available at http://www.hhs.gov/ash/initiatives/hai/introduction.html. Accessed April 25, 2011. 2. Mandatory reporting of healthcare performance measures. Association for Professionals in Infection Control and Epidemiology, Inc. Web site. Available at: http://www.apic.org/AM/Template.cfm?Section=Mandatory_Reporting#Introduction. Accessed April 25, 2011. 3. Mermel LA, McCormick RD, Springman SR, Maki DG. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med. 1991;91(suppl 3B):197S-205S. 4. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994;15:231-238. 5. O’Grady NP, Alexander M, Burns LA, et al; and the Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections, 2011. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html. Accessed April 26, 2011. 6. Fey PD, Matthews KI, Peterson DK, Iwen PC, Hinrichs SH, Rupp ME. Inhibitory effect of explanted chlorhexidine-silver sulfadiazine impregnated central venous catheters on Staphylococcus epidermidis. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 19, 2000; Toronto, ON, Canada. 7. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med. 2004;30:62-67. 8. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter–related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997;127:257-266. 9. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter–related infections. Ann Intern Med. 2005;143:570-580. 10. Data on file, Teleflex Incorporated. 11. Alarcon W. Preventing needlesticks in surgical personnel. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/niosh/blog/nsb031708_needlesticks.html. Accessed April 25, 2011.